Tougher Medicare rules for vitamin B12 tests under $365 million pathology savings plan
Last week's federal budget finally took up a handful of MBS Review recommendations from 2018.
Health officials are cracking down on Medicare-funded vitamin B12 and urine examination requests as part of a $365 million budget savings plan.
From July next year, MBS item 66839 for quantification of B12 marker such as holotranscobalamin and methylmalonic acid (schedule fee $42.95) will be limited to once per patient per year as recommended by the MBS Review Taskforce back in 2018.
